Clinical experience on EGFR tyrosine kinase inhibitor in non-small cell lung cancer, compassionate programme in Czech Republic

被引：0
|
作者：
Pesek, M.
Skrickova, J.
Kolek, V.
Zatloukal, P.
Petruzelka, L.
Svobodnik, A.
机构：
[1] Fac Med, Dept TB & Pulm Dis, Plzen, Czech Republic
[2] Fac Med, Dept TB & Pulm Dis, Brno, Czech Republic
[3] Fac Med, Dept TB & Pulm Dis, Olomouc, Czech Republic
[4] Fac Med, Dept Pneumol & Thorac Surg, Prague 8, Czech Republic
[5] Fac Med, Dept Oncol Dis, Prague 2, Czech Republic
[6] Masaryk Univ, Ctr Biostat & Anal, Brno, Czech Republic
来源：
LUNG CANCER | 2006年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 50 条
  • [31] Osteoblastic progression during EGFR tyrosine kinase inhibitor therapy in mutated non-small cell lung cancer: a potential blunder
    Bersanelli, Melissa
    Bini, Paola
    Rabaiotti, Enrico
    Facchinetti, Francesco
    De Filippo, Massimo
    Bortesi, Beatrice
    Buti, Sebastiano
    Tiseo, Marcello
    TUMORI, 2017, 103 (01) : 66 - 71
  • [32] MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Chen, Chao-Ju
    Liu, Yu-Peng
    PHARMACEUTICALS, 2021, 14 (02) : 1 - 25
  • [33] The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer
    Kang, Noeul
    Kim, Ki Hwan
    Jeong, Byeong-Ho
    Lee, Kyungjong
    Kim, Hojoong
    Kwon, O. Jung
    Ahn, Myung-Ju
    Cho, Jeonghee
    Lee, Ho Yun
    Um, Sang-Won
    CANCER RESEARCH AND TREATMENT, 2022, 54 (03): : 817 - 826
  • [34] Upregulation of HER3 and MET in non-small cell lung cancer cells resistant to EGFR tyrosine kinase inhibitor
    Larsen, Margaret
    Lyu, Hui
    Tan, CongCong
    Wu, Yakun
    Liu, Bolin
    CANCER RESEARCH, 2024, 84 (06)
  • [35] Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
    Alfredo Tartarone
    Rosa Lerose
    Chiara Lazzari
    Vanesa Gregorc
    Michele Aieta
    Medical Oncology, 2014, 31
  • [36] Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer
    Kole, Eknath
    Jadhav, Krishna
    Singh, Raghuraj
    Mandpe, Shilpa
    Abhang, Ashwin
    Verma, Rahul K.
    Naik, Jitendra
    CURRENT DRUG DELIVERY, 2025, 22 (03) : 249 - 260
  • [37] New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy
    Lee, Ho Yun
    Lee, Kyung Soo
    Ahn, Myung-Ju
    Hwang, Hye Sun
    Lee, Ju Won
    Park, Keunchil
    Ahn, Jin Seok
    Kim, Tae Sung
    Yi, Chin A.
    Chung, Myung Jin
    LUNG CANCER, 2011, 73 (01) : 63 - 69
  • [38] Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib
    Guttman-Yassky, Emma
    Mita, Alain
    De Jong, Maja
    Matthews, Lesley
    McCarthy, Sean
    Iwata, Kenneth K.
    Verweij, Jaap
    Rowinsky, Eric K.
    Krueger, James G.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 2010 - 2019
  • [39] Proposal of new CT response criteria in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor
    Lee, H.
    Lee, K.
    Ahn, M.
    Hwang, H.
    Lee, J.
    Park, K.
    Kim, T.
    Yi, C.
    Chung, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Mobocertinib EGFR ex20ins-specific tyrosine kinase inhibitor Treatment for non-small cell lung cancer
    Guo, Matthew Z.
    Marrone, Kristen A.
    Spira, Alexander
    Scott, Susan C.
    DRUGS OF THE FUTURE, 2022, 47 (03) : 181 - 189
12345